Ecallantide
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 176 publications
Sebetralstat (Ekterly) for treatment of hereditary angioedema attacks.
Journal: The Medical letter on drugs and therapeutics
Published: February 06, 2026
Barely There But Existent: Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
Journal: Cureus
Published: October 07, 2025
Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: December 11, 2024
Targeting the contact-kinin system: A cyclopeptide with anti-thromboinflammatory properties against stroke.
Journal: European journal of pharmacology
Published: November 04, 2024
Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines.
Journal: The Journal of allergy and clinical immunology
Published: October 31, 2024
Extension of the circulatory half-life of recombinant ecallantide via albumin fusion without loss of anti-kallikrein activity.
Journal: Journal of biotechnology
Published: March 18, 2024
A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors.
Journal: PLoS computational biology
Published: January 29, 2024
Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks.
Journal: Allergy and asthma proceedings
Published: November 22, 2023
A Case of Status Epilepticus in a Patient Experiencing an Acute Attack of Hereditary Angioedema.
Journal: Clinical practice and cases in emergency medicine
Published: October 31, 2023
Safety of medications for hereditary angioedema during pregnancy and lactation.
Journal: Expert opinion on drug safety
Published: February 06, 2023
Last Updated: 04/28/2026